Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy-Reference-Cited by-同舟云学术

Modified EASIX scores predict severe CRS/ICANS in patients with acute myeloid leukemia following CLL1 CAR-T cell therapy

Published:2024-01-12 Issue:3 Volume:103 Page:969-980
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Zhao Yifan,Zhang Xiaomei,Zhang Meng,Guo Ruiting,Zhang Yi,Pu Yedi,Zhu Haibo,Liu Pengjiang,Zhang Yu,He Xiaoyuan,Lyu Cuicui,Lyu Hairong,Xiao Xia,Zhao Mingfeng

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00277-024-05617-y.pdf

Reference32 articles.

1. O'Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, Gavin D, Lee S, Liu K, George B, Bryan W, Theoret MR, Pazdur R (2019) FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res : an official J Am Assoc Cancer Res 25(4):1142–1146. https://doi.org/10.1158/1078-0432.Ccr-18-2035

2. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M et al (2022) Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England J Med 386(7):640–654. https://doi.org/10.1056/NEJMoa2116133

3. Marvin-Peek J, Savani BN, Olalekan OO, Dholaria B (2022) Challenges and advances in chimeric antigen receptor therapy for acute myeloid leukemia. Cancers 14(3). https://doi.org/10.3390/cancers14030497

4. Hofmann S, Schubert ML, Wang L, He B, Neuber B, Dreger P, Müller-Tidow C, Schmitt M (2019) Chimeric antigen receptor (CAR) T cell therapy in acute myeloid leukemia (AML). J Clin Med 8(2). https://doi.org/10.3390/jcm8020200

5. Marshall AS, Willment JA, Pyz E, Dennehy KM, Reid DM, Dri P, Gordon S, Wong SY, Brown GD (2006) Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur J Immunol 36(8):2159–2169. https://doi.org/10.1002/eji.200535628

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic toxicity of CAR-T therapy and potential monitoring indicators for toxicity prevention;Frontiers in Immunology;2024-08-26